Century Therapeutics (IPSC) Debt to Equity (2020 - 2026)

Century Therapeutics (IPSC) has 6 years of Debt to Equity data on file, last reported at $0.01 in Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.01, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $0.01 (changed N/A YoY), and the FY2025 annual result was $0.02, changed N/A from the prior year.
• Debt to Equity declined to $0.01 in Q1 2026 per IPSC's latest filing, from $0.02 in the prior quarter.
• Over five years, Debt to Equity peaked at $0.05 in Q3 2025 and troughed at $0.01 in Q1 2026.
• A 4-year average of $0.03 and a median of $0.03 in 2022 frame the typical range for Debt to Equity.
• The sharpest annual moves came in 2022 and 2023: Debt to Equity surged 34.82% in 2022, then soared 43.39% in 2023.
• A 4-year view of Debt to Equity shows it stood at $0.03 in 2022, then rose by 9.82% to $0.04 in 2023, then plunged by 36.37% to $0.02 in 2025, then sank by 69.02% to $0.01 in 2026.
• Business Quant data shows IPSC's Debt to Equity at $0.01 in Q1 2026, $0.02 in Q4 2025, and $0.05 in Q3 2025.